These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

488 related items for PubMed ID: 17335310

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [POET2 registry: Comparison of annual direct medical costs of treating type 2 diabetes after addition of insulin NPH or insulin glargine to oral antidiabetic therapy in the Czech Republic].
    Kvapil M, Žďarská DJ, Suchopár J, Prokeš M, Brož J.
    Vnitr Lek; 2015 Jan; 61(1):24-32. PubMed ID: 25693613
    [Abstract] [Full Text] [Related]

  • 26. Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes treated with insulin glargine or NPH insulin.
    Dailey GE, Gao L, Aurand L, Garg SK.
    Diabetes Obes Metab; 2013 Dec; 15(12):1085-92. PubMed ID: 23683002
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Improved glycemic control with decreased hypoglycemia prevents long-term complications in type 2 diabetes patients: long-term simulation analysis using the "diabetes mellitus model".
    Maxion-Bergemann S, Huppertz E, Jacobs LD, Müller E, Walleser S.
    Int J Clin Pharmacol Ther; 2005 Jun; 43(6):271-81. PubMed ID: 15968884
    [Abstract] [Full Text] [Related]

  • 29. Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.
    Ridderstråle M, Jensen MM, Gjesing RP, Niskanen L.
    J Med Econ; 2013 Jun; 16(4):468-78. PubMed ID: 23384160
    [Abstract] [Full Text] [Related]

  • 30. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes.
    Massi Benedetti M, Humburg E, Dressler A, Ziemen M.
    Horm Metab Res; 2003 Mar; 35(3):189-96. PubMed ID: 12734781
    [Abstract] [Full Text] [Related]

  • 31. Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naïve type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting.
    Goodall G, Jendle JH, Valentine WJ, Munro V, Brandt AB, Ray JA, Roze S, Foos V, Palmer AJ.
    Int J Clin Pract; 2008 Jun; 62(6):869-76. PubMed ID: 18479280
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review.
    Caires de Souza AL, de Assis Acurcio F, Guerra Júnior AA, Rezende Macedo do Nascimento RC, Godman B, Diniz LM.
    Appl Health Econ Health Policy; 2014 Feb; 12(1):19-32. PubMed ID: 24385261
    [Abstract] [Full Text] [Related]

  • 35. Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH: A post hoc, pooled, patient-level analysis of 6 randomized controlled trials.
    Porcellati F, Lin J, Lucidi P, Bolli GB, Fanelli CG.
    Medicine (Baltimore); 2017 Feb; 96(5):e6022. PubMed ID: 28151905
    [Abstract] [Full Text] [Related]

  • 36. Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study.
    Sharplin P, Gordon J, Peters JR, Tetlow AP, Longman AJ, McEwan P.
    Cardiovasc Diabetol; 2009 Jan 19; 8():3. PubMed ID: 19152692
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Long-term efficacy of insulin glargine after switching from NPH insulin as intensive replacement of basal insulin in Japanese diabetes mellitus. Comparison of efficacy between type 1 and type 2 diabetes (JUN-LAN Study 1.2).
    Kanazawa Y, Igarashi Y, Komiya K, Sakurai Y, Shimizu T, Fujitani Y, Tanaka Y, Watada H, Kawamori R, Hirose T.
    Endocr J; 2007 Dec 19; 54(6):975-83. PubMed ID: 18000343
    [Abstract] [Full Text] [Related]

  • 40. Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes.
    Garg SK, Paul JM, Karsten JI, Menditto L, Gottlieb PA.
    Diabetes Technol Ther; 2004 Oct 19; 6(5):589-95. PubMed ID: 15628812
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.